J Korean Cancer Assoc.  1999 Oct;31(5):867-875.

Cermline Mutation of RET Gene in A Multiple Endocrine Neoplasia Type 2A ( MEN2A ) Family

Affiliations
  • 1Korean Hereditary Tumor Registry, Cancer Research Institute, Korea.
  • 2Department of Surgery, Seoul National University College of Medicine, Korea.
  • 3Department of General Surgery, Dae-Dong Hospital, Korea.

Abstract

PURPOSE: Multiple Endocrine Neoplasia Type 2A (MEN 2A) is an autosomal dominant disease characterized by development of the medullary thyroid cancer, adrenal pheochromocytoma and parathyroid hyperplasia. Gennline mutations of RET gene, which cause a susceptibility to MEN 2A syndrome, have been reported in MEN 2A families. The identification of germline mutation in family members with hereditary tumor syndrome makes the presymptomatic diagnosis possible. However, there are only a few reports on the germline mutation of RET gene in Korean patients with MEN 2A. This study was performed to investigate the germline mutation of RET gene in a Korean MEN 2A family.
MATERIALS AND METHODS
Blood samples were taken from family members of a MEN 2A family. Mutational status was investigated using single strand conformation polymorphism (SSCP) method, and following direct sequencing. Basal level of calcitonin was measured, and calcium provocation test was done when the result of basal level of calcitonin was equivocal.
RESULTS
A missense type germline mutation of RET gene was identified at codon 634 (TGC->TGG) in eight patients from the family. All patients with the germline mutation of RET gene showed elevation of calcitonin level either in basal test or in calcitonin provocation test.
CONCLUSION
We identified a germline mutation of RET gene in a family with MEN 2A, and it would make the accurate presymptomatic diagnosis possible.

Keyword

MEN 2A; Medullary thyroid cancer; RET gene; Calcitonin
Full Text Links
  • JKCA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr